ScholarLens Back to search
2010•Medical Journal of Chinese People's HealthRequires access

The clinical research of Mirtazapine combined Risperidone in the treatment of negative symptoms of schizophrenia

Chang Yu-shan

Open publisher page 0 citations

Abstract

Objective:To evaluate clinical efficacy and safety of Mirtazapine combined Risperidone in the treatment of negative symptoms of schizophrenia.Methods:136 patients with predominantly negative symptoms of schizophrenia were randomly divided into study group(Mirtazapine combined Risperidone) and the control group(Risperidone alone) with10 weeks' treatment.PANSS and TESS assessed the efficacy and safety respectively.Results: After treatment,PANSS scores were significantly lower before treatment(P0.05).4,6,8,10 week after treatment,the negative factor scores of study group were significantly lower than the control group,the difference was significant(P0.05 or P0.01).Two groups of adverse events were mild to moderate.Conclusions: Mirtazapine combined Risperidone in the treatment of schizophrenia with negative symptoms of rapid onset,better efficacy,fewer side effects,and good patient compliance.

About this research paper

What this paper is about

Objective:To evaluate clinical efficacy and safety of Mirtazapine combined Risperidone in the treatment of negative symptoms of schizophrenia.Methods:136 patients with predominantly negative symptoms of schizophrenia were randomly divided into study group(Mirtazapine combined Risperidone) and the control group(Risperidone alone) with10 weeks' treatment.PANSS and TESS assessed the efficacy and safety respectively.Results: After treatment,PANSS scores were significantly lower before treatment(P0.05).4,6,8,10 week after treatment,the negative factor scores of study group were significantly lower than the control group,the difference was significant(P0.05 or P0.01).Two groups of adverse events were mild to moderate.Conclusions: Mirtazapine combined Risperidone in the treatment of schizophrenia with negative symptoms of rapid onset,better efficacy,fewer side effects,and good patient compliance.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective:To evaluate clinical efficacy and safety of Mirtazapine combined Risperidone in the treatment of negative symptoms of schizophrenia.Methods:136 patients with predominantly negative symptoms of schizophrenia were randomly divided into study group(Mirtazapine combined Risperidone) and the control group(Risperidone alone) with10 weeks' treatment.PANSS and TESS assessed the efficacy and safety respectively.Results: After treatment,PANSS scores were significantly lower before treatment(P0.05).4,6,8,10 week after treatment,the negative factor scores of study group were significantly lower than the control group,the difference was significant(P0.05 or P0.01).Two groups of adverse events were mild to moderate.Conclusions: Mirtazapine combined Risperidone in the treatment of schizophrenia with negative symptoms of rapid onset,better efficacy,fewer side effects,and good patient compliance.

Key concepts: Risperidone, Mirtazapine, Schizophrenia (object-oriented programming), Negative symptom, Medicine, Adverse effect, Internal medicine, Clinical efficacy

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
The clinical research of Mirtazapine combined Risperidone in the treatment of negative symptoms of schizophrenia — Research Paper | ScholarLens